Study #2018-0646
Tagraxofusp (SL-401) therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN) patients post-autologous or post-allogeneic hematopoietic cell transplantation
MD Anderson Study Status
Not Accepting
Treatment Agent
Tagraxofusp-erzs
Description
This phase II trial studies the side effects of tagraxofusp in treating patients with blastic plasmacytoid dendritic cell neoplasm after stem cell transplant. Tagraxofusp is a type of immunotoxin that is made by linking a protein called IL-3 to a toxic substance. Tagraxofusp may help find cancer cells that express IL-3 and kill them without harming normal cells.
Information and next steps
Disease:
Blastic Plasmacytoid Dendritic Cell Neoplasm
Study phase:
II
Physician name:
Qaiser Bashir
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.